{"id":745735,"date":"2018-04-15T15:50:00","date_gmt":"2018-04-15T15:50:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\/"},"modified":"2025-11-07T01:27:23","modified_gmt":"2025-11-07T06:27:23","slug":"updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\/","title":{"rendered":"Updated Overall Survival Data for LYNPARZA\u00ae (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR"},"content":{"rendered":"<p>\n      AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States<br \/>\n      and Canada, today presented data from the Phase 3 OlympiAD trial showing<br \/>\n      the final overall survival (OS) results for LYNPARZA<i> <\/i>in<br \/>\n      metastatic breast cancer at the American Association for Cancer Research<br \/>\n      (AACR) Annual Meeting in Chicago from April 14-18.\n    <\/p>\n<p>\n      The trial compared LYNPARZA<i> <\/i>with chemotherapy (physician\u2019s choice<br \/>\n      of capecitabine, eribulin or vinorelbine) for patients with germline <i>BRCA<\/i>-mutated<br \/>\n      (g<i>BRCA<\/i>m), HER2-negative metastatic breast cancer and met its<br \/>\n      primary endpoint of progression-free survival (PFS).\n    <\/p>\n<p>\n      Results at AACR include updated findings from the secondary endpoint of<br \/>\n      overall survival (OS). While the trial was not powered to demonstrate a<br \/>\n      statistically significant difference, the median OS was 19.3 months in<br \/>\n      patients treated with<i> <\/i>LYNPARZA and 17.1 months for patients<br \/>\n      treated with chemotherapy (HR 0.90, 95% CI 0.66-1.23; p=0.513). At the<br \/>\n      final OS data cutoff (64% maturity), 13 percent of patients remained on<br \/>\n      LYNPARZA and no patients remained on chemotherapy.\n    <\/p>\n<p>\n      Sean Bohen, executive vice president, global medicines development and<br \/>\n      chief medical officer at AstraZeneca, said, \u201cOlympiAD is the first Phase<br \/>\n      3 trial to demonstrate disease control with a PARP inhibitor in g<i>BRCA-<\/i>mutated,<br \/>\n      HER2-negative metastatic breast cancer. While the trial was not powered<br \/>\n      to show overall survival compared to chemotherapy, the results are<br \/>\n      another encouraging factor in the use of LYNPARZA<i> <\/i>for this<br \/>\n      patient population.\u201d\n    <\/p>\n<p>\n      Dr. Roy Baynes, senior vice president and head of global clinical<br \/>\n      development, chief medical officer, Merck Research Laboratories, said,<br \/>\n      \u201cFor patients and physicians, these results are meaningful in that they<br \/>\n      support the progression-free survival endpoint \u2013 which showed that<br \/>\n      patients treated with\u00a0LYNPARZA<i>\u00a0<\/i>gained seven<br \/>\n      months\u00a0chemotherapy-free time \u2013 and reinforce the importance of<br \/>\n      identifying\u00a0<i>BRCA <\/i>status to optimize metastatic breast cancer<br \/>\n      management.\u201d\n    <\/p>\n<p>\n      When analyzing the predefined subgroups, the results were consistent<br \/>\n      with the overall analysis, which did not show a statistically<br \/>\n      significant difference between arms. The greatest difference was seen in<br \/>\n      patients who had not received chemotherapy in the metastatic setting<br \/>\n      with a median difference in OS of 7.9 months with LYNPARZA<i> <\/i>(HR<br \/>\n      0.51, 95% CI 0.29-0.90; nominal p=0.02; median 22.6 vs 14.7 months).\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"21\">\n<p class=\"bwcellpmargin\">\n            <b>Table 1: Predefined subgroups for OS analysis<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"5\">\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>Subgroup<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"5\">\n          <b>Median OS<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(months)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>HR<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>95% CI<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>Nominal <i>P<\/i>*<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>LYNPARZA<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Physician\u2019s choice<\/b><br \/>\n<br \/>\n<b>of chemotherapy<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          <b>Prior chemotherapy for metastatic breast cancer<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl bwsinglebottom\">\n          No (1L)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          22.6\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          14.7\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.51\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.29-0.90\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.02\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl bwsinglebottom\">\n          Yes (2L\/3L)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          18.8\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          17.2\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1.13\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.79-1.64\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.52\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          <b>Prior platinum-based chemotherapy for breast cancer<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl bwsinglebottom\">\n          No\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          20.3\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          19.6\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.91\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.64-1.33\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.63\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl bwsinglebottom\">\n          Yes\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          17.2\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          13.3\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.83\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.49-1.45\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.49\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          <b>Receptor status<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Oestrogen receptor positive (ER+) and\/or progesterone receptor<br \/>\n          positive (HR+)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          21.8\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          21.3\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.86\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.55-1.36\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.51\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Triple-negative breast cancer (TNBC)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          17.4\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          14.9\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.93\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.62-1.43\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.75\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      The safety profile of LYNPARZA remained consistent with the primary<br \/>\n      analysis. Serious adverse events (AEs) (Grade \u22653) were reported in 38<br \/>\n      percent of patients who received LYNPARZA vs 49.5% of patients in the<br \/>\n      chemotherapy arm. AEs leading to drug discontinuation were 4.9 percent<br \/>\n      for LYNPARZA vs 7.7 percent for chemotherapy. AEs leading to dose<br \/>\n      reductions were 25.4 percent for LYNPARZA vs 30.8 percent for<br \/>\n      chemotherapy. AEs leading to dose interruptions were 36.1 percent for<br \/>\n      LYNPARZA vs 28.6 percent for chemotherapy. <b>Please see Important<br \/>\n      Safety Information below.<\/b>\n    <\/p>\n<p>\n      These results build on previously reported primary and secondary<br \/>\n      endpoints, which demonstrated LYNPARZA<i> <\/i>significantly improved PFS<br \/>\n      (HR 0.58, 95% CI 0.43-0.80; p=0.0009 median 7.0 vs 4.2 months) and<br \/>\n      showed data beyond initial disease progression, prolonging time to<br \/>\n      second progression or death (PFS2) by 3.9 months (HR 0.57, 95% CI<br \/>\n      0.40-0.83; P=0.003 median 13.2 months vs 9.3 months). Previously<br \/>\n      reported findings also showed LYNPARZA\u00a0doubled objective response rates<br \/>\n      (52% [95% CI 44-60] vs 23% [95% CI 13-35]). The data from the OlympiAD<br \/>\n      trial can be found in the August 10 2017 issue of the <i>New England<br \/>\n      Journal of Medicine.<\/i>\n    <\/p>\n<p>\n      In January 2018, LYNPARZA<i> <\/i>was approved by the U.S. Food and Drug<br \/>\n      Administration (FDA) for use in the treatment of g <i>BRCA<\/i>-mutated<br \/>\n      metastatic breast cancer based on the OlympiAD data. A Type 2 Variation<br \/>\n      application was recently validated by the European Medicines Agency for<br \/>\n      LYNPARZA<i> <\/i>in <i>BRCA<\/i>-mutated, HER2-negative metastatic breast<br \/>\n      cancer.\n    <\/p>\n<p>\n      A Phase 3 trial (n=1800), OlympiA, is evaluating LYNPARZA as an adjuvant<br \/>\n      treatment in patients with g<i>BRCA,<\/i> HER2-negative breast cancer<br \/>\n      with results expected in 2020. The trial is powered to assess potential<br \/>\n      benefit in OS.\n    <\/p>\n<p>\n      LYNPARZA is approved in around 60 countries for advanced ovarian cancer<br \/>\n      and has treated more than 20,000 patients globally. It has the broadest<br \/>\n      clinical development program of any PARP inhibitor, and AstraZeneca and<br \/>\n      Merck are working together to bring LYNPARZA to more patients across<br \/>\n      multiple cancers.\n    <\/p>\n<p>\n      <b>Important Safety Information for LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b><br \/>\n      (olaparib)<\/b>\n    <\/p>\n<p>\n      <b>Contraindications<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b>\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML): <\/b>Occurred<br \/>\n      in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the majority<br \/>\n      of events had a fatal outcome. The duration of therapy in patients who<br \/>\n      developed secondary MDS\/AML varied from 2 years. All of<br \/>\n      these patients had previous chemotherapy with platinum agents and\/or<br \/>\n      other DNA-damaging agents, including radiotherapy, and some also had a<br \/>\n      history of more than one primary malignancy or of bone marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood count for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood count<br \/>\n      weekly until recovery.\n    <\/p>\n<p>\n      If the levels have not recovered to Grade 1 or less after 4 weeks, refer<br \/>\n      the patient to a hematologist for further investigations, including bone<br \/>\n      marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA<br \/>\n      (olaparib) if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis: <\/b>Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt LYNPARZA treatment and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity: <\/b>Based on its mechanism of action and<br \/>\n      findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is<br \/>\n      recommended for females of reproductive potential prior to initiating<br \/>\n      treatment.\n    <\/p>\n<p>\n      <i>Females<\/i>\n    <\/p>\n<p>\n      Advise females of reproductive potential of the potential risk to a<br \/>\n      fetus and to use effective contraception during treatment and for 6<br \/>\n      months following the last dose.\n    <\/p>\n<p>\n      <i>Males<\/i>\n    <\/p>\n<p>\n      Advise male patients with female partners of reproductive potential or<br \/>\n      who are pregnant to use effective contraception during treatment and for<br \/>\n      3 months following the last dose of LYNPARZA and to not donate sperm<br \/>\n      during this time.\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Maintenance Setting<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting <\/b>for <b>SOLO-2<\/b>:<br \/>\n      nausea (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting<br \/>\n      (37%), nasopharyngitis\/upper respiratory tract infection (URI)\/influenza<br \/>\n      (36%), diarrhea (33%), arthralgia\/myalgia (30%), dysgeusia (27%),<br \/>\n      headache (26%), decreased appetite (22%), and stomatitis (20%). <b>Study<br \/>\n      19: <\/b>nausea (71%), fatigue (including asthenia) (63%), vomiting<br \/>\n      (35%), diarrhea (28%), anemia (23%), respiratory tract infection (22%),<br \/>\n      constipation (22%), headache (21%), and decreased appetite (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting (SOLO-2\/Study<br \/>\n      19<\/b>) were: increase in mean corpuscular volume (89%\/82%), decrease in<br \/>\n      hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in<br \/>\n      lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%),<br \/>\n      increase in serum creatinine (44%\/45%), and decrease in platelets<br \/>\n      (42%\/36%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Advanced g<i>BRCA<\/i>m Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA (olaparib) for <b>advanced g<i>BRCA<\/i>m<br \/>\n      ovarian cancer after 3 or more lines of chemotherapy <\/b>(pooled from 6<br \/>\n      studies) were: fatigue (including asthenia) (66%), nausea (64%),<br \/>\n      vomiting (43%), anemia (34%), diarrhea (31%), nasopharyngitis\/upper<br \/>\n      respiratory tract infection (URI) (26%), dyspepsia (25%), myalgia (22%),<br \/>\n      decreased appetite (22%), and arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer <\/b>(pooled<br \/>\n      from 6 studies) were: decrease in hemoglobin (90%), increase in mean<br \/>\n      corpuscular volume (57%), decrease in lymphocytes (56%), increase in<br \/>\n      serum creatinine (30%), decrease in platelets (30%), and decrease in<br \/>\n      absolute neutrophil count (25%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014g<i>BRCA<\/i>m, HER2-Negative Breast Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in <b>OlympiAD<\/b><br \/>\n      were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%),<br \/>\n      vomiting (30%), neutropenia (27%), respiratory tract infection (27%),<br \/>\n      leukopenia (25%), diarrhea (21%), and headache (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in <b>OlympiAD<br \/>\n      <\/b>were: decrease in hemoglobin (82%), decrease in lymphocytes (73%),<br \/>\n      decrease in leukocytes (71%), increase in mean corpuscular volume (71%),<br \/>\n      decrease in absolute neutrophil count (46%), and decrease in platelets<br \/>\n      (33%).\n    <\/p>\n<p>\n      <b>Drug Interactions<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents: <\/b>Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors: <\/b>Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be<br \/>\n      co-administered, reduce the dose of LYNPARZA. Advise patients to avoid<br \/>\n      grapefruit, grapefruit juice, Seville oranges, and Seville orange juice<br \/>\n      during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers: <\/b>Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA (olaparib). If a moderate inducer cannot be<br \/>\n      avoided, there is a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>Use In Specific Populations<\/b>\n    <\/p>\n<p>\n      <b>Lactation: <\/b>No data are available regarding the presence of<br \/>\n      olaparib in human milk, its effects on the breastfed infant or on milk<br \/>\n      production. Because of the potential for serious adverse reactions in<br \/>\n      the breastfed infant, advise a lactating woman not to breastfeed during<br \/>\n      treatment with LYNPARZA and for 1 month after receiving the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use: <\/b>The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Hepatic Impairment: <\/b>No adjustment to the starting dose is<br \/>\n      required in patients with mild hepatic impairment (Child-Pugh<br \/>\n      classification A). There are no data in patients with moderate or severe<br \/>\n      hepatic impairment.\n    <\/p>\n<p>\n      <b>Renal Impairment: <\/b>No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment (CLcr=51-80 mL\/min). In patients<br \/>\n      with moderate renal impairment (CLcr=31-50 mL\/min), reduce the dose to<br \/>\n      200 mg twice daily. There are no data in patients with severe renal<br \/>\n      impairment or end-stage renal disease (CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>Dosing and Administration<\/b>\n    <\/p>\n<p>\n      To avoid substitution errors and overdose, <b>do not substitute LYNPARZA<\/b><br \/>\n      <b>tablets with LYNPARZA capsules <\/b>on a milligram-to-milligram basis<br \/>\n      due to differences in the dosing and bioavailability of each<br \/>\n      formulation. Recommended tablet dose is 300 mg, taken orally twice<br \/>\n      daily, with or without food. Continue treatment until disease<br \/>\n      progression or unacceptable toxicity. For adverse reactions, consider<br \/>\n      dose interruption or dose reduction.\n    <\/p>\n<p>\n      <b>Indications for LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae <\/b><br \/>\n<\/sup><br \/>\n<b>(olaparib) in the<br \/>\n      U.S.<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with recurrent<br \/>\n      epithelial ovarian, fallopian tube, or primary peritoneal cancer, who<br \/>\n      are in complete or partial response to platinum-based chemotherapy.\n    <\/p>\n<p>\n      For the treatment of adult patients with deleterious or suspected<br \/>\n      deleterious germline <i>BRCA-<\/i>mutated (g<i>BRCA<\/i>m) advanced<br \/>\n      ovarian cancer who have been treated with 3 or more prior lines of<br \/>\n      chemotherapy. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      In patients with deleterious or suspected deleterious g<i>BRCA<\/i>m,<i> <\/i>human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative metastatic breast<br \/>\n      cancer who have previously been treated with chemotherapy in the<br \/>\n      neoadjuvant, adjuvant or metastatic setting. Patients with hormone<br \/>\n      receptor (HR)-positive breast cancer should have been treated with a<br \/>\n      prior endocrine therapy or be considered inappropriate for endocrine<br \/>\n      treatment. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Please see complete\u00a0<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.azpicentral.com%2Flynparza_tb%2Fpi_lynparza_tb.pdf%23page%3D1&amp;esheet=51788890&amp;newsitemid=20180415005099&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=1&amp;md5=235fff10e70f77ad5f510df9c6b8c849\" rel=\"nofollow\"><br \/>\n<b>Prescribing<br \/>\n      Information<\/b><br \/>\n<\/a><br \/>\n<b> for LYNPARZA (olaparib), including Patient<br \/>\n      Information (Medication Guide)<\/b>\n    <\/p>\n<p>\n      <b>NOTES TO EDITORS<\/b>\n    <\/p>\n<p>\n      <b>About OlympiAD<\/b>\n    <\/p>\n<p>\n      OlympiAD is a global, randomized, open-label, multi-center Phase 3 trial<br \/>\n      of 302 patients, assessing the efficacy and safety of LYNPARZA tablets<br \/>\n      (300 mg twice daily) compared to chemotherapy (physician\u2019s choice of<br \/>\n      capecitabine, eribulin or vinorelbine). 205 patients were randomized to<br \/>\n      receive LYNPARZA and 97 patients were randomized to receive chemotherapy.\n    <\/p>\n<p>\n      Patients in the OlympiAD trial had germline <i>BRCA<\/i>-mutated,<br \/>\n      HER2-negative breast cancer and received LYNPARZA<i> <\/i>for treatment<br \/>\n      in the metastatic setting. Prior to enrollment, 71 percent of patients<br \/>\n      had received no more than two previous chemotherapy treatments for<br \/>\n      metastasized breast cancer and 28 percent of patients had received prior<br \/>\n      platinum-based chemotherapy. Also enrolled were patients with hormone<br \/>\n      receptor (HR)-positive breast cancer who had received at least one<br \/>\n      endocrine therapy (adjuvant therapy or therapy for metastatic disease)<br \/>\n      and had disease progression during therapy unless they had disease for<br \/>\n      which the endocrine therapy was considered inappropriate.\n    <\/p>\n<p>\n      The primary endpoint was PFS. Secondary endpoints included OS, time to<br \/>\n      second progression or death, overall response rate, health-related<br \/>\n      quality of life, and safety and tolerability.\n    <\/p>\n<p>\n      <b>About Metastatic Breast Cancer<\/b>\n    <\/p>\n<p>\n      Progesterone receptors (PR), estrogen receptors (ER) and HER2 receptors<br \/>\n      may be expressed on breast cancer cells. A patient\u2019s breast cancer will<br \/>\n      test either negative or positive for these three receptors. If a tumor<br \/>\n      tests positive for PR and\/or ER, it is considered HR-positive. If a<br \/>\n      tumor tests negative for all three receptors, it is considered triple<br \/>\n      negative. These receptors indicate which hormones or other proteins may<br \/>\n      be promoting growth of the cancer.\n    <\/p>\n<p>\n      Metastatic breast cancer (MBC) is the most advanced stage of breast<br \/>\n      cancer (Stage 4), and occurs when cancer cells have spread beyond the<br \/>\n      initial tumor site to other parts of the body, outside of the breast and<br \/>\n      nearby lymph nodes.\n    <\/p>\n<p>\n      Despite the increase in treatment options during the past three decades,<br \/>\n      there is currently no cure for patients diagnosed with MBC and only 26.9<br \/>\n      percent of patients survive for five years after diagnosis. Thus, the<br \/>\n      primary aim of treatment is to slow progression of the disease for as<br \/>\n      long as possible, improving, or at least maintaining, a patient\u2019s<br \/>\n      quality of life.\n    <\/p>\n<p>\n      Breast cancer is the most common cancer in women, with an estimated 1.67<br \/>\n      million new cases diagnosed worldwide in 2012 alone &#8211; one in four of all<br \/>\n      cancer cases. Approximately 30 percent of women who are diagnosed with<br \/>\n      early breast cancer will go on to develop advanced disease.\n    <\/p>\n<p>\n      <b>About <i>BRCA <\/i>Mutations<\/b>\n    <\/p>\n<p>\n      <i>BRCA<\/i>1 and <i>BRCA<\/i>2 are human genes that produce proteins<br \/>\n      responsible for repairing damaged DNA and play an important role<br \/>\n      maintaining the genetic stability of cells. When either of these genes<br \/>\n      is mutated, or altered, such that its protein product either is not made<br \/>\n      or does not function correctly, DNA damage may not be repaired properly<br \/>\n      and cells become unstable. As a result, cells are more likely to develop<br \/>\n      additional genetic alterations that can lead to cancer.\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA<i> <\/i>was the first in class PARP inhibitor and the first<br \/>\n      targeted treatment to potentially exploit DNA damage response (DDR)<br \/>\n      pathway deficiencies, such as <i>BRCA<\/i> mutations, to preferentially<br \/>\n      kill cancer cells. Specifically, <i>in vitro<\/i> studies have shown that<br \/>\n      LYNPARZA-induced cytotoxicity may involve inhibition of PARP enzymatic<br \/>\n      activity and increased formation of PARP-DNA complexes, resulting in DNA<br \/>\n      damage and cancer cell death.\n    <\/p>\n<p>\n      LYNPARZA, which has the broadest clinical development program of any<br \/>\n      PARP inhibitor, is being investigated in a range of DDR-deficient tumor<br \/>\n      types.\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      In July 2017, AstraZeneca and Merck, known as MSD outside the United<br \/>\n      States and Canada announced a global strategic oncology collaboration to<br \/>\n      co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP<br \/>\n      inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. The collaboration is based on increasing evidence<br \/>\n      that PARP and MEK inhibitors can be combined with PD-L1\/PD-1 inhibitors<br \/>\n      for a range of tumor types. Working together, the companies will develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as a monotherapy. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      oncology and we are accelerating every step in the journey \u2013 from lab to<br \/>\n      clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry evaluating oncology medicines in more than 30<br \/>\n      tumor types. We also continue to strengthen our oncology portfolio<br \/>\n      through strategic acquisitions and are prioritizing the development of<br \/>\n      several promising candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51788890&amp;newsitemid=20180415005099&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=3138c58deb1814314c2bad72e69ca1fe\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51788890&amp;newsitemid=20180415005099&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=6586c7c21bc83d879be16fd466831975\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and\u00a0connect with us on\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51788890&amp;newsitemid=20180415005099&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=336bd7314a4e1e90bead00849a95bd19\" rel=\"nofollow\">Twitter<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51788890&amp;newsitemid=20180415005099&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=9e59a7acdc4de480a5076fde4ef5fc18\" rel=\"nofollow\">Facebook<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51788890&amp;newsitemid=20180415005099&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=b7dcf8be1865261bf5870d23d33d2389\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51788890&amp;newsitemid=20180415005099&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=cacd52d6ccd95c3b95e390f3783617a0\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51788890&amp;newsitemid=20180415005099&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=358aafc16881396819a5b3de027c1f0f\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. If underlying assumptions prove<br \/>\n      inaccurate or risks or uncertainties materialize, actual results may<br \/>\n      differ materially from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51788890&amp;newsitemid=20180415005099&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=a9f9d9075f402b75aa91692a56f5175e\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180415005099r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/> Media: <br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Courtney        Ronaldo, 908-740-6132<br \/>or<br \/> Investors: <br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Michael DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data from the Phase 3 OlympiAD trial showing the final overall survival (OS) results for LYNPARZA in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 14-18. The trial compared LYNPARZA with chemotherapy (physician\u2019s choice of capecitabine, eribulin or vinorelbine) for patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer and met its primary endpoint of progression-free survival (PFS). Results at AACR include updated findings from the secondary endpoint of overall survival (OS). While the trial was not powered to demonstrate a statistically significant difference, the median OS was 19.3 months in patients treated with LYNPARZA and 17.1 months for patients treated with chemotherapy (HR 0.90, 95% CI 0.66-1.23; p=0.513). At the final OS data cutoff (64% maturity), 13 percent of patients<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,289,56],"class_list":["post-745735","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Updated Overall Survival Data for LYNPARZA\u00ae (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Updated Overall Survival Data for LYNPARZA\u00ae (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR - Merck.com\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data from the Phase 3 OlympiAD trial showing the final overall survival (OS) results for LYNPARZA in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 14-18. The trial compared LYNPARZA with chemotherapy (physician\u2019s choice of capecitabine, eribulin or vinorelbine) for patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer and met its primary endpoint of progression-free survival (PFS). Results at AACR include updated findings from the secondary endpoint of overall survival (OS). While the trial was not powered to demonstrate a statistically significant difference, the median OS was 19.3 months in patients treated with LYNPARZA and 17.1 months for patients treated with chemotherapy (HR 0.90, 95% CI 0.66-1.23; p=0.513). At the final OS data cutoff (64% maturity), 13 percent of patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\\\/\",\"name\":\"Updated Overall Survival Data for LYNPARZA\u00ae (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-04-15T15:50:00+00:00\",\"dateModified\":\"2025-11-07T06:27:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Updated Overall Survival Data for LYNPARZA\u00ae (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Updated Overall Survival Data for LYNPARZA\u00ae (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\/","og_locale":"en_US","og_type":"article","og_title":"Updated Overall Survival Data for LYNPARZA\u00ae (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR - Merck.com","og_description":"AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data from the Phase 3 OlympiAD trial showing the final overall survival (OS) results for LYNPARZA in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 14-18. The trial compared LYNPARZA with chemotherapy (physician\u2019s choice of capecitabine, eribulin or vinorelbine) for patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer and met its primary endpoint of progression-free survival (PFS). Results at AACR include updated findings from the secondary endpoint of overall survival (OS). While the trial was not powered to demonstrate a statistically significant difference, the median OS was 19.3 months in patients treated with LYNPARZA and 17.1 months for patients treated with chemotherapy (HR 0.90, 95% CI 0.66-1.23; p=0.513). At the final OS data cutoff (64% maturity), 13 percent of patients","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:23+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\/","name":"Updated Overall Survival Data for LYNPARZA\u00ae (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-04-15T15:50:00+00:00","dateModified":"2025-11-07T06:27:23+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Updated Overall Survival Data for LYNPARZA\u00ae (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"4ffc276a-04e0-412d-b320-55b6c3104e81","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":3,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745735\/revisions"}],"predecessor-version":[{"id":3675094,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745735\/revisions\/3675094"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745735"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}